Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
AKT1 Structural Domains and Key Mutations
AKT1 (PKBα) is a serine/threonine kinase with three key functional domains: an N-terminal PH domain (pleckstrin homology) that binds phosphoinositides, a central Protein kinase domain (AGC kinase family), and a C-terminal AGC-kinase domain critical for activation. Key mutations include the oncogenic hotspot E17K (PH domain gain-of-function, enhances membrane localization) found in PROTEUSS, breast, colorectal, and ovarian cancers. Other mutations include CWS6 (impairs PIP2/PIP3 interaction) and rs11555433 (variant of unknown significance).
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AKT/AKT1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | AKT1 Full Length / Mutant Protein (e.g., E17K) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View AKT1 Products |
| Gene Delivery | AKT1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View AKT1 Products |
| Benchmark Ab | Anti-AKT1 (Phospho-T308 / S473 specific) Recombinant positive control for target engagement assays. |
View AKT1 Products |
| Validator | AKT1 siRNA Set For knockdown verification in functional assays. |
View AKT1 Products |
| Related Target A | PIK3CA Upstream kinase partner, critical for dual-inhibition and resistance bypassing. |
View PIK3CA Products |
| Related Target B | mTOR Downstream effector, frequently targeted in vertical pathway inhibition. |
View mTOR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (AKT1 vs AKT2/3) | Human Ortholog and Isoform panels available with >95% purity for precise counter-screening. |
| Drug Resistance Modeling | Clinically relevant mutant variants (e.g., E17K) rigorously sequence-verified and mass spec confirmed. |
| Lack of Target Engagement Controls | Phospho-specific Benchmark Antibodies included for robust PD (pharmacodynamic) biomarker readouts. |
| False Positives in Degradation | Valid siRNA included for exact specificity checks in PROTAC workflows. |
Live AKT/AKT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AKT/AKT1 therapeutics has entered a mature phase, with major players advancing from first-generation ATP-competitive inhibitors to highly selective allosteric modulators and novel degraders. Following the clinical validation of AKT inhibition in HR-positive breast cancer, the next wave of R&D is intensely targeting mutant-specific conformations (such as AKT1 E17K) and bypassing the dose-limiting toxicities associated with wild-type and pan-AKT inhibition. Combination therapies, particularly pairing AKT inhibitors with endocrine therapy or upstream PI3K inhibitors, represent the dominant future strategy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Allosteric Small Molecule | AstraZeneca, Roche, Merck | HR+ Breast Cancer, Prostate Cancer | Selectivity Assay (Need High-purity Isoform Proteins) |
| Targeted Protein Degrader (PROTAC) | Novartis, Arvinas | Refractory Solid Tumors | Degradation Validation (Need Lentiviral Cell Lines & Controls) |
| ATP-competitive Inhibitor | Bayer, GSK | PTEN-deficient Cancers | Kinase Activity Assay (Need Active Full-length Proteins) |